Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Top Downloads
    • Annual Meeting Abstracts
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • Rights and Permissions
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine

Nicolas J Blobel, Andrei Ramirez-Valdez, Andrew S Ishizuka, Geoffrey M Lynn and Robert A Seder
J Immunol May 1, 2017, 198 (1 Supplement) 73.20;
Nicolas J Blobel
Vaccine Research Center, NIAID, NIH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrei Ramirez-Valdez
Vaccine Research Center, NIAID, NIH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew S Ishizuka
Vaccine Research Center, NIAID, NIH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey M Lynn
Avidea Technologies
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A Seder
Vaccine Research Center, NIAID, NIH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Induction of T cell immunity against neoantigens of cancers is a promising personalized vaccine approach against tumors. We developed a novel vaccine platform to enhance the breadth and magnitude of neoantigen-specific CD8 T cell responses by coupling neoantigen peptides to a polymer containing a Toll-Like Receptor-7/8 agonist that self-assembles into nanoparticles (termed SPP-7/8a). As the SPP-7/8 vaccine platform can be formulated to immunize against multiple neoantigen peptides, a critical issue is how the delivery influences the magnitude and breadth of CD8 T cell responses. Thus, C57BL/6 mice were injected subcutaneously against a single neoantigen at either a single site, or divided across four sites. CD8 T cell responses were ~3% in the mice immunized at multiple sites compared to ~1% at a single injection site. To assess breadth, mice were immunized with four antigens, with either a single antigen at each of four injection sites or a combination of all four antigens across four injection sites. In mice that received all four antigens in each site, CD8 T cell responses against two of the antigens were undetectable. By contrast, in animals that received 1 antigen per site, responses were detected against all four antigens, and the total magnitude was higher than animals receiving 4 antigens per site. Collectively, these data suggest that despite increasing the CD8 T cell response of a single antigen via multi-site injection, vaccination even with as few as 4 antigens can interfere with the induction of neoantigen-specific CD8 T cells. Current work is focused on altering the delivery of the SPP-7/8a immunization approach to optimize both magnitude and breadth of CD8 T cell immunity that will be critical for tumor treatment and protection.

  • Copyright © 2017 by The American Association of Immunologists, Inc.
Previous
Back to top

In this issue

The Journal of Immunology
Vol. 198, Issue 1 Supplement
1 May 2017
  • Table of Contents
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
Citation Tools
Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine
Nicolas J Blobel, Andrei Ramirez-Valdez, Andrew S Ishizuka, Geoffrey M Lynn, Robert A Seder
The Journal of Immunology May 1, 2017, 198 (1 Supplement) 73.20;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antigenic competition affects the magnitude and breadth of CD8 T cell immunity following immunization with a nanoparticle neoantigen cancer vaccine
Nicolas J Blobel, Andrei Ramirez-Valdez, Andrew S Ishizuka, Geoffrey M Lynn, Robert A Seder
The Journal of Immunology May 1, 2017, 198 (1 Supplement) 73.20;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

  • Induction of CXCR5+ follicular CD8 T cells by CD40L adjuvanted DNA/MVA vaccination is associated with enhanced control of pathogenic SHIV infection.
  • CAR NK and CAR T cells versus CTL: factors limiting the sensitivity and efficiency of engineered cytolytic effectors
  • Breadth of function and homing capacity of peripheral CD4+ Th responses to intradermal (ID) immunization with enterotoxigenic E. coli fimbrial tip adhesin CfaE plus adjuvant LTR192G
Show more Late-Breaking Vaccines and Immunotherapy

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2019 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606